Compare iShares MSCI China ETF (MCHI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Sana Biotechnology Inc — how do they compare? iShares MSCI China ETF trades at $52.53 (market cap $5.94B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: iShares MSCI China ETF is far larger — about 7.1× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is more actively traded (4,507,444 versus 1,575,471). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Sana Biotechnology Inc for 23 Days on average.
| MCHI | SANA | |
|---|---|---|
Market Cap | $5.94B | $836.71M |
Volume | 1,575,471 | 4,507,444 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $5.92 |
52-Week Low | $50.48 | $2.68 |
Typical Hold Time | 63 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $52.46, up 1.59% today, but faces strong bearish technical signals with 13 sell signals on moving averages. The ETF's valuation remains historically cheap compared to US indices, with Seeking Alpha noting the discount despite significant tech exposure. Recent news highlights China's economic challenges including industrial overcapacity and trade tensions ahead of key US-China meetings.
Outlook remains cautious given bearish technicals and China's macroeconomic headwinds, though the valuation discount presents potential opportunity. Key risks include US-China trade tensions and weak domestic consumption. Institutional activity shows mixed signals with recent purchases by Empowered Funds offset by sales from Acima Private Wealth.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
